Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Q2 Earnings Call In Brief

This article was originally published in The Gray Sheet

Executive Summary

Endeavor DES: Medtronic is on track to file IDE for Endeavor III confirmatory study in the "next few weeks and begin [a] study here in the U.S. in late December," Medtronic CEO Art Collins tells investors Nov. 12, during a quarterly earnings call. The Endeavor II pivotal trial has crossed its midway point, with 600 of 1200 patients enrolled, the exec also notes, commenting that safety and toxicity data for the firm's ABT-578 drug compound are favorable. Medtronic continues to forecast a European DES launch in late 2004 and a U.S. release at the end of 2005 (1"The Gray Sheet" September 22, 2003, p. 8)....
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT019334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel